Plasma GAS6 predicts mortality risk in acute heart failure patients: insights from the DRAGON-HF trial.

ABSTRACT:

Background

Growth arrest-specific 6 (GAS6) is a vitamin K-dependent protein related to inflammation, fibrosis, as well as platelet function. Genetic ablation of GAS6 in mice protects against cardiac hypertrophy and dysfunction. Nonetheless, the association between plasma GAS6 levels and acute heart failure (AHF) patients is still unknown.

Methods

We measured plasma GAS6 concentrations in 1039 patients with AHF who were enrolled in the DRAGON-HF trial (NCT03727828). Mean follow-up of the study was 889 days. The primary endpoint is all-cause death.

Results

In total, there were 195 primary endpoints of all-cause death and 135 secondary endpoints of cardiovascular death during the mean follow-up duration of 889 days. The higher levels of GAS6 were associated with higher r

SUBMITTER: Ma T 

PROVIDER: S-EPMC9838057 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature